8-K: Astrana Health Reports Mixed Q3 Results, Raises Full-Year Revenue Guidance

Astrana Health announced its third-quarter 2024 financial results, showing strong revenue growth but a decline in net income and adjusted EBITDA compared to the same period last year.

Summary

• Astrana Health reported a 37% increase in total revenue for the third quarter of 2024, reaching $478.7 million, up from $348.2 million in the same quarter of 2023.
• Care Partners revenue saw a significant 42% increase, totaling $455.8 million.
• However, net income attributable to Astrana decreased by 27% to $16.1 million, and diluted earnings per share (EPS) fell by 30% to $0.33.
• Adjusted EBITDA also declined by 13% to $45.2 million.
• For the nine months ended September 30, 2024, total revenue increased by 32% to $1,369.3 million, and net income attributable to Astrana rose by 4% to $50.1 million.
• Adjusted EBITDA for the nine-month period increased by 15% to $135.3 million.
• The company has raised its full-year revenue guidance to a range of $1.95 billion to $2.03 billion, while narrowing its net income guidance to $52 million to $58 million, adjusted EBITDA to $165 million to $175 million, and EPS to $1.06 to $1.19.
• Astrana Health completed the acquisition of Collaborative Health Systems (CHS) on October 4, 2024, for $37.5 million plus potential earnout payments of up to $21.5 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with strong revenue growth but declining profitability metrics. The raised revenue guidance is positive, but the decrease in net income and adjusted EBITDA raises concerns. The sentiment is cautiously optimistic.

Positives

• Astrana Health experienced strong revenue growth in the third quarter of 2024, with a 37% increase year-over-year.
• Care Partners revenue saw a substantial 42% increase, indicating strong performance in this segment.
• The company's total revenue for the first nine months of 2024 increased by 32% compared to the same period in 2023.
• Adjusted EBITDA for the first nine months of 2024 increased by 15% compared to the same period in 2023.
• The acquisition of Collaborative Health Systems (CHS) expands Astrana's network and market reach.
• The company has raised its full-year revenue guidance, reflecting confidence in future performance.

Negatives

• Net income attributable to Astrana decreased by 27% in the third quarter of 2024 compared to the same period in 2023.
• Diluted earnings per share (EPS) decreased by 30% in the third quarter of 2024 compared to the same period in 2023.
• Adjusted EBITDA decreased by 13% in the third quarter of 2024 compared to the same period in 2023.
• The company's net income growth for the first nine months of 2024 was only 4%, despite a 32% increase in revenue.

Risks

• The company's financial results are subject to risks and uncertainties, as detailed in their SEC filings.
• The integration of acquired companies, such as CHS, may present challenges.
• The company's ability to meet its financial guidance is not guaranteed.
• There is a risk that actual financial results may vary materially from the company's expectations.
• The company's adjusted EBITDA was lower relative to the same period last year due to a timing difference in when certain incentive dollars were booked and the move to accruing ACO results throughout the year.

Future Outlook

Astrana Health has raised its full-year 2024 revenue guidance to a range of $1.95 billion to $2.03 billion and narrowed its net income guidance to $52 million to $58 million, adjusted EBITDA to $165 million to $175 million, and EPS to $1.06 to $1.19. The company anticipates continued growth and expansion of its value-based care model.

Management Comments

• Astrana's strong third quarter continues to reflect the outcomes we are driving with the Astrana care model and value-based care enablement platform, said President and CEO of Astrana, Brandon K. Sim.
• We continued to see strong organic and inorganic growth across our businesses while delivering high-quality care and managing costs effectively in the quarter.
• We are confident in our platforms ability to continue improving access, quality, and coordination of care for around 1.1 million patients in local communities nationwide.

Industry Context

Astrana Health's focus on value-based care and technology-enabled healthcare aligns with broader industry trends towards more efficient and patient-centric healthcare delivery. The acquisition of CHS is a strategic move to expand its network and market presence, which is a common strategy among healthcare providers seeking to increase scale and market share.

Comparison to Industry Standards

• While Astrana's revenue growth is strong, the decline in net income and adjusted EBITDA in Q3 2024 is a concern, especially when compared to other healthcare companies that have shown more consistent profitability.
• Companies like Oak Street Health and Agilon Health, which also operate in the value-based care space, have been closely watched for their ability to balance growth with profitability.
• Astrana's adjusted EBITDA margin of 9% for Q3 2024 is lower than some industry benchmarks, indicating potential challenges in cost management.
• The company's focus on acquisitions is similar to other players in the market, but the success of these acquisitions will depend on effective integration and realization of synergies.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and adjusted EBITDA, despite the revenue growth.
• Employees may be affected by the integration of acquired companies and any potential changes in operations.
• Customers (patients) should benefit from the expansion of Astrana's network and services.
• Suppliers and creditors may see increased business opportunities with the company's growth.

Next Steps

• Astrana Health will host a conference call on November 7, 2024, to discuss the third-quarter results.
• The company will continue to integrate the recently acquired Collaborative Health Systems (CHS).
• Astrana Health will focus on executing its strategic growth plans and improving its financial performance.

Key Dates

Keywords

Astrana Health, healthcare, financial results, revenue, net income, EBITDA, adjusted EBITDA, earnings per share, acquisition, value-based care, care partners, care delivery, care enablement, Medicare Advantage